RBM19

Across TCGA pan-cancer cohorts, RBM19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM19 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RBM19 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM19 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where RBM19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.799	1.000	.001	73	view →
LSCC	DFS	Median	All	0.989	0.888	.003	28	view →
PDAC	DFS	Tertile	II,III,IV	0.668	0.835	.003	22	view →
LUAD	OS	Median	III,IV	0.808	0.294	.019	4	view →
HNSC	DFS	Quartile	IV	0.523	0.786	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM19–CCRCC (OS)

Open the CCRCC breakdown →